

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 8, 2024

Myosin Light Chain 2/MLC-2V antibody

RRID:AB_2147453

Type: Antibody

Proper Citation

(Proteintech Cat# 10906-1-AP, RRID:AB_2147453)

Antibody Information

URL: http://antibodyregistry.org/AB_2147453

Proper Citation: (Proteintech Cat# 10906-1-AP, RRID:AB_2147453)

Target Antigen: Myosin Light Chain 2/MLC-2V

Host Organism: rabbit

Clonality: polyclonal

Comments: Originating manufacturer of this product.

Applications: WB, IP, IHC, IF, FC, ELISA

Antibody Name: Myosin Light Chain 2/MLC-2V antibody

Description: This polyclonal targets Myosin Light Chain 2/MLC-2V

Target Organism: human, monkey, mouse, rat, zebrafish

Antibody ID: AB_2147453

Vendor: Proteintech

Catalog Number: 10906-1-AP

Ratings and Alerts

No rating or validation information has been found for Myosin Light Chain 2/MLC-2V antibody.

No alerts have been found for Myosin Light Chain 2/MLC-2V antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Marchiano S, et al. (2023) Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy. *Cell stem cell*, 30(4), 396.

Sun YH, et al. (2023) The sinoatrial node extracellular matrix promotes pacemaker phenotype and protects automaticity in engineered heart tissues from cyclic strain. *Cell reports*, 42(12), 113505.

Busley AV, et al. (2023) Generation of a genetically-modified induced pluripotent stem cell line harboring a Noonan syndrome-associated gene variant MRAS p.G23V. *Stem cell research*, 69, 103108.

Dark N, et al. (2023) Generation of left ventricle-like cardiomyocytes with improved structural, functional, and metabolic maturity from human pluripotent stem cells. *Cell reports methods*, 3(4), 100456.

Prasad V, et al. (2022) Loss of cardiac myosin light chain kinase contributes to contractile dysfunction in right ventricular pressure overload. *Physiological reports*, 10(7), e15238.

Ng WH, et al. (2022) Recapitulating human cardio-pulmonary co-development using simultaneous multilineage differentiation of pluripotent stem cells. *eLife*, 11.

Shah PP, et al. (2021) Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. *Cell stem cell*, 28(5), 938.

Ding Y, et al. (2021) Derivation of iPSC lines from two patients with autism spectrum disorder carrying NRXN1? deletion (NUIGi041-A, NUIG041-B; NUIGi045-A) and one sibling control (NUIGi042-A, NUIGi042-B). *Stem cell research*, 52, 102222.

Sun X, et al. (2020) Hydrogen sulfide regulates muscle RING finger-1 protein S-sulfhydration at Cys44 to prevent cardiac structural damage in diabetic cardiomyopathy. *British journal of pharmacology*, 177(4), 836.

Kleinsorge M, et al. (2020) Subtype-Directed Differentiation of Human iPSCs into Atrial and Ventricular Cardiomyocytes. STAR protocols, 1(1), 100026.

Wang H, et al. (2019) Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. Cell systems, 8(5), 412.

Mills RJ, et al. (2019) Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell stem cell, 24(6), 895.

Fernandez-Perez A, et al. (2019) Hand2 Selectively Reorganizes Chromatin Accessibility to Induce Pacemaker-like Transcriptional Reprogramming. Cell reports, 27(8), 2354.